How to Appeal an Orforglipron (Foundayo) Denial: Steps, Deadlines & a Free Appeal Letter
Don’t send a generic appeal letter. Decode the denial first — then pick the lane that actually wins.
By The RX Index Editorial Team · Last verified: . The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We may earn a commission from some provider links — that never changes what we verify or what we tell you to do first, which on this page is free. This guide is consumer information, not medical or legal advice.
The short version:
If you’re trying to figure out how to appeal an orforglipron denial, don’t write a generic appeal letter yet. First, find the exact reason on your denial letter — because each reason has a different fix.
- →“Missing information” usually means a corrected prior authorization — a redo, not a fight. Often days, not months.
- →“Not medically necessary” means a real internal appeal with records. Most private plans give you 180 days to file.
- →“Non-formulary” — because Foundayo was approved on April 1, 2026, this may be a calendar problem, not a clinical judgment. Different fix than a medical denial.
Start here: find your denial in 10 seconds
| Your denial letter says… | Your lane | Your first move |
|---|---|---|
| "Missing information" / "PA incomplete" | Corrected prior authorization | Ask exactly what was missing, then fix it |
| "Not medically necessary" / "criteria not met" | Internal appeal | Get your doctor's letter + records |
| "Step therapy required" | Step-therapy exception | Ask which drugs they want tried first |
| "Non-formulary" / "not covered drug" | Formulary exception | Ask what GLP-1s they do cover |
| "Weight-loss drugs excluded" | Benefits exception or backup plan | Confirm in your plan document — then jump to the exclusion section below |
| Medicare denial | Bridge program or Part D appeal | Check the $50 Bridge rules before anything else |
Not sure which row is yours, or want your letter built automatically?
Check your GLP-1 coverage on Ro — free → (sponsored affiliate link, opens in a new tab)Contacts your insurer and sends a personalized report on what your plan covers — before you write a single sentence.
Why was your orforglipron (Foundayo) prescription denied?
Answer capsule
Insurers deny Foundayo for six main reasons, and each one needs a different response — sending a generic appeal to the wrong denial type is the most common way people lose. The denial letter names the reason. If it doesn’t, federal rules require the insurer to tell you why and how to appeal, so ask for the reason in writing.
The timing detail almost nobody tells you
The FDA approved Foundayo on April 1, 2026. So if your denial says “non-formulary” or “not on our drug list,” the problem may be plan-formulary timing, not a clinical judgment about you. New drugs get added to plan drug lists on a review cycle — a brand-new one can land before the plan has finished that review. That has a different fix than a medical denial: a formulary exception, not a standard appeal.
The Foundayo Denial Decoder
Find the wording closest to your letter. Then you’ll know your move before you write a single sentence.
| What your letter says | What it usually means | The right move | What to attach | Honest reality check |
|---|---|---|---|---|
| "Prior authorization required" | No final decision was ever made — they want forms first | Have your prescriber submit (or resubmit) the PA. This isn't a true denial yet. | The insurer's current PA form, BMI, diagnosis codes, medication history | Outdated forms get auto-rejected. Ask for the current one. |
| "Missing information" | The request may be fixable without a formal appeal | Ask exactly what was missing; submit a corrected PA | The exact missing item, plus the denial letter | Often the fastest win on this whole page |
| "Not medically necessary" | They say their criteria weren't proven | Internal appeal with a clinician letter | Letter of medical necessity, BMI history, conditions, prior treatment attempts | This is the lane where an appeal is the right tool |
| "BMI criteria not met" | Your weight history or related conditions weren't documented | Corrected PA if data was missing; appeal if it was there and ignored | Baseline BMI, current BMI, diagnosis codes for related conditions | If your BMI is 27–29.9, a properly coded condition can open the door |
| "Lifestyle program documentation required" | They want proof you tried diet/exercise first | Corrected PA with records | Program records, clinician notes, app receipts, dates | "I tried diets" in your own words won't count. Dated records will. |
| "Step therapy required" | They want you to try a preferred drug first | Step-therapy exception — or comply if the alternative fits you | Records of past medication trials, intolerance, or contraindications | Exception paths exist at all major insurers, but they require documentation |
| "Non-formulary" | Foundayo isn't on the drug list (often because it's new) | Formulary exception request | Your doctor's note on why covered GLP-1s aren't right for you | A standard appeal is the wrong tool here — request the exception |
| "Weight-loss drugs excluded" | The benefit may not exist in your plan at all | Don't draft a normal appeal. See the exclusion section below. | Your plan document | This is the one denial paperwork usually can't fix |
Not sure which row is yours? The 3-minute phone script
Call the pharmacy/member services number on your insurance card and say:
“Hi — I’m calling about a denied prior authorization for Foundayo, generic name orforglipron. I have three questions.
One: What is the exact denial reason and denial code?
Two: Can you send me your written coverage criteria for this drug?
Three: Can this be fixed with a corrected prior authorization — or do I need to file a formal appeal? And what’s my deadline?”
Write down the rep’s name, today’s date, and the call reference number. You’ll want all three later.
Know your reason (or want help finding it)?
Check your GLP-1 coverage with Ro — free → (sponsored affiliate link, opens in a new tab)Contacts your insurer and reports back exactly what your plan covers.
Should you appeal, fix the PA, or request an exception?
Answer capsule
There are three different “fight back” tools, and they are not interchangeable. A corrected prior authorization re-submits with the missing piece added. An internal appeal formally challenges a decision the plan already made. An exception request asks the plan to cover something outside its normal rules. Using an appeal when you needed a corrected PA can add weeks.
| Tool | Use it when… | Speed |
|---|---|---|
| Corrected PA | The denial was clerical — missing info, wrong form, no PA on file | Often the fastest path; days to a couple of weeks |
| Internal appeal | The plan reviewed your case and denied it on its criteria | Plan must decide within 30 days for care you haven't gotten yet |
| Formulary / step-therapy exception | The drug isn't on the list, or they want a different drug tried first | Varies by plan; ask for the expedited track if your health can't wait |
| External review | Your internal appeal lost | An outside reviewer decides within 45 days (72 hours expedited) |
How to appeal orforglipron denial — step by step
To appeal an orforglipron denial: get the denial reason in writing, gather evidence that answers that specific reason, have your prescriber write a letter of medical necessity, and submit through the channel named on your denial notice — within the deadline (180 days for most employer and marketplace plans). If the plan says no again, request an independent external review — the reviewer’s decision binds the insurer.
Get the denial reason in writing
Use the phone script above. Also request the plan's coverage criteria for Foundayo or GLP-1 medications (sometimes called a "clinical policy bulletin"). This document is the answer key — your appeal's only job is to match it.
Pick your lane with the Decoder
Corrected PA, appeal, or exception — the table above tells you which. Don't skip this. The lane decides everything you do next.
Gather your evidence — three buckets
- ·Weight records — BMI history showing 30+, or 27+ with at least one weight-related health condition
- ·Health condition documentation — diagnosed and coded conditions like high blood pressure, prediabetes, sleep apnea, or high cholesterol
- ·Proof of past attempts — dated records of diet, exercise, or weight programs, plus any weight medications you've tried before
Ask your prescriber for a letter of medical necessity
A letter of medical necessity (LMN) is a short letter from your prescriber explaining why you need this specific drug. The strongest LMNs cite the plan's own criteria point by point — and real outcome data. In the ATTAIN-1 trial that supported Foundayo's approval, people who stayed on the highest dose lost an average of 27.3 pounds (12.4%), versus 2.2 pounds (0.9%) on placebo. Your doctor can cite that as clinical trial evidence — not as a promise of personal results, but as established evidence base. That's very different from a vague note that just says the drug is needed.
Write the appeal to the denial reason — point by point
Your insurer isn't grading effort or emotion. It's checking boxes. Answer the exact reason they gave, attach the proof, and ask for a specific outcome ("approve coverage," "grant a formulary exception"). Keep it short and factual. The full skeleton is in the next section.
Submit the right way, before the deadline — and keep proof
Use the address or portal on your denial notice. If you mail it, send copies (never originals) by certified mail. Keep a log of every call and letter.
Calendar their deadline — and escalate if they say no
For care you haven't received yet, the plan must decide your internal appeal within 30 days (60 days for care you already got). If your health is at urgent risk, demand the expedited track — and run an external review at the same time as the appeal. If they uphold the denial, file for external review — an independent reviewer re-decides your case, and the insurer must follow the result.
Do appeals actually work? More than the denial letter wants you to feel.
- ✓Fewer than 1% of denied marketplace claims ever get appealed (KFF, 2024 data)
- ✓When people did appeal those claims, insurers upheld 66% — meaning about 34% of appeals were not upheld and the denial was reversed
- ✓In Medicare Advantage, 80.7% of appealed prior-authorization denials were partly or fully overturned (KFF, 2024)
These numbers aren’t Foundayo-specific — the drug is too new. But the pattern is consistent: most denials are never challenged, and a real share of the ones that are get reversed. The most avoidable reason a denial stands is that nobody pushes back.
Ready to put yours on paper? Ro’s free coverage check can tell you exactly where your plan stands before you write a word.
Check my GLP-1 coverage — free → (sponsored affiliate link, opens in a new tab)What should your Foundayo appeal letter say?
Answer capsule
A strong Foundayo appeal letter answers the specific denial reason — it doesn’t argue that obesity treatment matters in general. It identifies the claim, states why the denial reason is wrong or incomplete, attaches objective records, includes the prescriber’s letter of medical necessity, and asks for a specific outcome by a specific process.
The appeal letter skeleton — top to bottom
- 1Your info: Name, member ID, claim/reference number, denial date
- 2The medication: Foundayo (orforglipron), the prescribed dose
- 3The denial reason, quoted: Copy their exact words back to them
- 4Why that reason is wrong or incomplete: One short paragraph, factual — not emotional
- 5FDA-label eligibility: Foundayo is FDA-approved for adults with obesity, or adults with overweight plus at least one weight-related health condition
- 6Your records: BMI history, conditions, prior attempts (listed, with attachments)
- 7Why covered alternatives don't fit you: Only if clinically true, in your doctor's words
- 8The ask: "I request that you approve coverage" or "I request a formulary exception," plus your right to escalate
Two traps to avoid
- ✗Don’t copy a random GLP-1 appeal letter off the internet and swap in “Foundayo” — plans notice, and generic letters don’t answer their criteria
- ✗Don’t lean on feelings (“I really need this”). Lean on documents. Short, factual, specific wins.
The quiet move that rescues borderline cases
If your BMI is 27–29.9, eligibility usually hinges on a documented weight-related condition. A sleep study confirming sleep apnea, or recent labs showing prediabetes, properly diagnosed and coded by your doctor, can be the difference between “criteria not met” and approved.
Evidence guide — what to gather and why it matters
| Evidence | Why it matters | Who provides it |
|---|---|---|
| Denial letter | Names the exact target your appeal must hit | You / your plan |
| Plan's coverage criteria | The answer key your appeal must match | Insurer or PBM (pharmacy benefit manager) |
| BMI and weight history | Proves FDA label eligibility | Your clinician's records |
| Coded diagnoses | Opens the BMI 27–29.9 pathway | Your clinician |
| Diet/exercise/program records | Answers the most common documentation requirement | You + clinician |
| Letter of medical necessity | Connects your facts to their criteria | Your prescriber |
| Prior medication history | Powers step-therapy exceptions | Prescriber / pharmacy records |
What are the deadlines for a Foundayo appeal?
Answer capsule
For most employer and marketplace plans, you have 180 days from the denial notice to file an internal appeal, and the plan must decide within 30 days (before care) or 60 days (after). If you lose, you have 4 months to request external review, decided within 45 days — or 72 hours when expedited. Medicare drug plans: 65 days to request a redetermination.
| Plan type | Your deadline to act | Their deadline to decide | If they say no again |
|---|---|---|---|
| Employer or marketplace — internal appeal | 180 days from denial | 30 days (care not received) · 60 days (care received) · urgent: at least within 4 business days of request | Request external review |
| External review (independent reviewer) | 4 months from final internal denial | ≤45 days standard · ≤72 hours expedited | Decision binds the insurer; state complaint or legal routes remain |
| Medicare Part D — exception request | Ask anytime; prescriber sends supporting statement | 72 hours standard · 24 hours expedited | File a redetermination |
| Medicare Part D — redetermination (level 1 appeal) | 65 days from denial notice | 7 days standard · 72 hours expedited | Independent Review Entity, then higher levels ($200 minimum for a judge hearing in 2026) |
| Medicare GLP-1 Bridge (from July 1, 2026) | Prescriber submits through central CMS process | Processed centrally | Standard Part D rules don't apply; runs outside Part D |
| Medicaid | Varies by state — your denial notice lists it | Varies by state | State fair hearing |
Pressure-release valve #1: expedited review
If waiting would seriously risk your health, demand the expedited track. In urgent cases, you can even run the external review at the same time as the internal appeal.
Pressure-release valve #2: external review is free
The federal external review process is free. Some state-run versions can charge, capped at $25. Miss your window, and the denial stands by default — calendar the date today.
What if your plan excludes weight-loss drugs completely?
The hardest denial to beat
A written weight-loss medication exclusion is the hardest denial to beat — the plan isn’t questioning your paperwork, it’s saying the benefit doesn’t exist in your contract. A standard medical-necessity appeal almost never overturns plan design. We’d rather tell you this plainly than let you burn six weeks on a letter that was never going to work.
Open your plan document (the long PDF, often called a Summary Plan Description) and search for “weight loss,” “anti-obesity,” or “weight management.” If the exclusion is written there, redirect your energy:
The employer lever
Your employer chooses what the plan covers — and because employers pay the premiums, plans listen when the benefits manager calls. Send this:
Subject: Request — coverage exception for an FDA-approved weight-management medication
“Hi [Name] — my doctor prescribed Foundayo (orforglipron), an FDA-approved weight-management medication, and our plan denied it because weight-loss medications are excluded. Could you ask our broker or carrier whether a coverage exception is possible, or whether adding GLP-1 coverage is being considered at renewal? I’m happy to share my denial letter and my doctor’s letter of medical necessity.”
Three sentences. Zero drama. Benefits teams field these constantly, and renewal-season requests genuinely shape next year’s plan.
The other lanes if exclusion is confirmed
- →On Medicare? The exclusion logic flips July 1 — next section
- →Need treatment before that? Cash-pay math starts at $149/month — a very different conversation than the $1,000+ list prices of injectable GLP-1s
If this denial has you rethinking the whole plan, our free 60-second quiz will show you which programs fit your situation — coverage fight or no coverage fight.
Take the free 60-second GLP-1 matching quiz →What if Medicare denied Foundayo? (The $50 Bridge opens July 1, 2026)
Answer capsule
Standard Part D generally does not cover drugs used solely for weight loss, which is why Part D denials for Foundayo have been routine. What changes on July 1, 2026 is the Medicare GLP-1 Bridge: a temporary CMS demonstration running through December 31, 2027 that gives eligible Part D enrollees access to Foundayo, Wegovy, or Zepbound KwikPen for a flat $50 monthly copay — through a central process that sits outside normal Part D coverage.
The smartest “appeal” may not be an appeal at all
If your denial came through regular Part D, in many cases the right move is no appeal — it’s having your prescriber file with the Bridge once it opens. As of June 12, 2026, that is 19 days away.
Do you qualify? The three eligibility tiers
Eligibility is judged at the time you started GLP-1 therapy — not today. See the detail below the table.
| Tier | You qualify if… |
|---|---|
| Tier 1 | BMI of 35 or higher |
| Tier 2 | BMI of 30+ plus heart failure with preserved ejection fraction, uncontrolled hypertension (systolic over 140 or diastolic over 90 despite treatment with two blood-pressure medications), or chronic kidney disease stage 3a or above |
| Tier 3 | BMI of 27+ plus prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease |
The detail that rescues people who already lost weight
Eligibility is judged as of when you first started GLP-1 therapy — not today. CMS’s own example: someone who started a GLP-1 in September 2024 at a BMI of 37, and is now at 34, still qualifies — the prescriber simply attests that the BMI-35 criterion was met at the start. If you were denied because your current BMI dropped below a cutoff after months of progress, this rule was written for you. Bring it to your prescriber.
The fine print — told straight
What does Foundayo cost while you appeal — or if you lose?
Answer capsule
Foundayo’s cash price is $149–$349 per month depending on dose through LillyDirect and select telehealth providers like Ro — and if your appeal later succeeds, you can switch to insurance pricing with the savings card, dropping eligible commercially insured patients to $25/month. You can run both tracks at once.
The play most people don’t realize is allowed:
Start cash-pay now so you don’t lose momentum. Keep the appeal moving. If you win, switch at a future refill. If you lose, you already know your worst-case number — and for the starting dose, it’s $149, not $1,300.
Every legitimate way to pay — on one grid
| Route | What you’d pay | Worth knowing |
|---|---|---|
| LillyDirect / Ro cash-pay | $149 (0.8 mg) · $199 (2.5 mg) · $299 (5.5 & 9 mg) · $299 (14.5 & 17.2 mg with manufacturer offer)* | Same medication prices both places. No insurance approval or PA needed for the cash price — prescription still required. |
| Foundayo Savings Card — plan covers it | As low as $25/month | Commercial insurance only. Max savings $100 per one-month fill, up to 10 fills/year. |
| Foundayo Savings Card — commercial plan does NOT cover it | Card caps cost at $149–$349 by dose | A real fallback while your appeal runs. |
| Medicare GLP-1 Bridge (from July 1, 2026) | $50/month if eligible | See tiers above. Medicare/Medicaid enrollees can't use the savings card. |
| TrumpRx | Lists Foundayo; routes to LillyDirect pricing | Same prices — it's a doorway, not a discount. |
*The honest gotcha: the $299 price on the two highest doses requires refilling within 45 days of your last fill. Miss the window and those doses revert to $349. Set a reminder. Also, the savings card’s current terms run through December 31, 2026, and Lilly can change them anytime — we re-verify monthly.
Can Ro help after a Foundayo denial?
Answer capsule
Ro is a telehealth provider that carries FDA-approved GLP-1s — including Foundayo and Zepbound — with Foundayo cash pricing of $149–$299/month when the manufacturer offer applies, matching LillyDirect’s prices. Ro also offers a free GLP-1 Insurance Coverage Checker that contacts your insurer and reports back what your plan covers.
Straight talk, because you’ve earned it after reading this far:
Ro does not make the pill itself cheaper. Foundayo’s cash price on Ro is the same $149–$299 you’d pay going directly through LillyDirect. If squeezing out every last dollar with zero support is your priority, going straight to LillyDirect with a prescription from your own doctor is the better fit — and we just showed you exactly how to do that.
But because Ro doesn’t compete on pill price, your membership buys the part of this process that just chewed you up: a licensed clinician who handles the prescription, ongoing care, a free coverage check before you spend another month guessing, and an insurance concierge that navigates coverage and submits prior-authorization paperwork for eligible insurance-covered GLP-1s. If your fight stalled because your doctor’s office won’t touch the paperwork, or you honestly don’t know whether your plan covers any GLP-1 — that’s the exact gap Ro may fill.
What to know plainly
“I was not expecting insurance help. Usually patients are their own advocate, so I was thrilled to not have to fight for my coverage.”
Best fit if:
- ✓You don't know what your plan covers
- ✓Your prescriber's office won't touch GLP-1 paperwork
- ✓You want a real clinician path, not just a discount card
- ✓You want a coverage read before spending more time fighting
Not the right fit if:
- ✗You already have a prescriber running your appeal and sending a script to LillyDirect
- ✗Your plan clearly excludes the medication you need
- ✗Squeezing every dollar with no support overhead is your priority
Does that sound like the help you’ve been missing?
Check your GLP-1 coverage on Ro — free → (sponsored affiliate link, opens in a new tab)See what your plan covers before you write another letter.
Prefer to pick your own doctor and compare branded options like Wegovy, Zepbound, Ozempic, and Foundayo across visit prices? Sesame Care is a solid second look (sponsored affiliate link, opens in a new tab) for self-pay shoppers who want provider choice.
Is there a cheaper or compounded version of orforglipron?
No — and this matters.
Orforglipron is a small-molecule, non-peptide oral GLP-1 with no FDA-approved generic. Do not treat anything marketed as “generic Foundayo” or “compounded orforglipron” as a legitimate lower-cost substitute — compounded drugs are not FDA-approved, and FDA rules restrict compounded products that are essentially copies of a commercially available, approved drug.
We run a comparison site for GLP-1 providers, including compounded ones, so we’d tell you if a legitimate cheaper route existed here. It doesn’t. The good news: at a $149/month starting price through the manufacturer’s own channel, Foundayo launched as one of the lowest cash-cost GLP-1 medications on the market.
When should you stop appealing?
Stop treating the appeal as the only path when the denial is a true written benefit exclusion, when deadlines or processing time would delay treatment longer than you can accept, when another FDA-approved GLP-1 is covered by your plan, or when your own clinician says Foundayo isn’t right for you. Knowing when to switch lanes isn’t quitting — it’s how you actually start treatment this month.
| Your situation | Your best next move |
|---|---|
| A document was missing | Corrected PA — not an appeal |
| Criteria met, but denied anyway | Internal appeal (180-day window) |
| Foundayo isn't on the formulary | Formulary exception |
| They want a different drug first | Step-therapy exception — or take the covered GLP-1 if it fits you |
| Employer plan excludes weight-loss drugs | HR/benefits exception request + backup plan |
| On Medicare and Bridge-eligible | Prescriber files with the Bridge after July 1 |
| No coverage path, but cash works | LillyDirect or Ro at $149–$299/month |
| Clinician says Foundayo isn't safe for you | Don't override your doctor — the fight is for access, not to overrule your clinician |
| Honestly not sure anymore | Our free 60-second matching quiz sorts this in one minute |
Still not sure which GLP-1 program is right for you?
Take our free 60-second matching quiz — you’ll get an action plan based on your medication goal, your insurance situation, and whether a coverage fight is even worth your time right now.
Take the free 60-second GLP-1 matching quiz →One safety check before you fight
Make sure Foundayo is still the right thing to fight for.
Foundayo carries a boxed warning about thyroid C-cell tumors; people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not take it. It should not be combined with other GLP-1 medications, and it’s approved for adults only.
Also discuss with your prescriber: pancreatitis symptoms; severe gastrointestinal reactions; dehydration or acute kidney injury risk; low blood sugar if you also use insulin or a sulfonylurea; a history of diabetic retinopathy; gallbladder symptoms; any planned surgery with anesthesia or deep sedation; strong interacting medications (including certain CYP3A4 drugs and simvastatin); pregnancy; the need for backup contraception for a period after starting and after each dose increase; and severe liver impairment. These are label-level safety issues, not appeal-letter details — that conversation comes before any letter.
How we built and verified this guide
The RX Index built this guide from primary sources: FDA and Eli Lilly materials for approval and pricing, HealthCare.gov and CMS for appeal deadlines and the Medicare GLP-1 Bridge, KFF analyses of federal data for appeal outcomes, and Ro’s published pages for its pricing and tools. Patient forums informed only the language and questions on this page — never the medical, legal, or coverage facts.
Provider-stated vs. what we verified ()
| Claim | Source’s stated figure | RX Index verified | Last verified |
|---|---|---|---|
| FDA approval | Foundayo approved April 1, 2026 | FDA press release + label checked | June 12, 2026 |
| FDA-labeled use | Adults with obesity, or overweight plus ≥1 weight-related condition, with reduced-calorie diet and increased activity | FDA label checked | June 12, 2026 |
| LillyDirect / Ro cash price | $149 / $199 / $299 by dose; high doses $299 with 45-day refill rule, otherwise $349 | Lilly + Ro pages checked | June 12, 2026 |
| Savings card | As low as $25/mo with commercial coverage; self-pay caps differ by dose; government plans excluded | Lilly + Ro terms checked | June 12, 2026 |
| Ro Coverage Checker | Contacts your insurer and sends a report; does not submit treatment requests or write prescriptions | Ro pages checked | June 12, 2026 |
| Ro insurance-covered GLP-1s | Wegovy pen, Zepbound autoinjector pen, and Ozempic listed as insurance-covered; Foundayo positioned as cash-pay | Ro how-it-works page checked | June 12, 2026 |
| Appeal deadlines | 180-day internal appeal; external review within 4 months (≤45 days / ≤72 hrs expedited); Part D redetermination within 65 days | HealthCare.gov + CMS checked | June 12, 2026 |
| Appeal outcomes | <1% of marketplace claims appealed, 66% upheld (2024); 80.7% of appealed MA prior-auth denials overturned (2024) | KFF analyses checked | June 12, 2026 |
| Medicare GLP-1 Bridge | July 1, 2026 – Dec 31, 2027; $50 copay; covers Foundayo, Wegovy pill/pen, Zepbound KwikPen; tiered eligibility | CMS Bridge pages checked | June 12, 2026 |
We re-verify pricing monthly and program rules quarterly (more often around July 1). We may earn a commission from some provider links on this page; it changes nothing about the facts above.
Frequently asked questions: appealing an orforglipron denial
- Can I appeal an orforglipron denial myself?
- Yes — you have the legal right to appeal your own denial, and your state's Consumer Assistance Program can help for free. You'll still need your prescriber to supply medical records and a letter of medical necessity, since those carry the clinical weight of the appeal.
- How long do I have to appeal a Foundayo denial?
- Most employer and marketplace plans give you 180 days from the denial notice for an internal appeal, and 4 months after a final denial to request external review. Medicare drug plans give you 65 days to request a redetermination. Your denial letter states your exact deadline — it controls.
- Should I appeal or just resubmit the prior authorization?
- Resubmit a corrected PA when the denial was clerical — missing information, wrong form, no PA on file. File a formal appeal when the plan reviewed your evidence and still said no. Using an appeal for a clerical denial can add weeks.
- How often do appeals like this actually win?
- There's no Foundayo-specific success rate yet — the drug is too new. But in 2024, when people appealed denied marketplace claims, insurers upheld 66% and reversed about 34%. And 80.7% of appealed Medicare Advantage prior-authorization denials were partly or fully overturned (KFF). The pattern: few denials are challenged, and a real share of the ones that are get reversed.
- What if Foundayo isn't on my plan's formulary?
- Request a formulary exception — your prescriber explains why the plan's covered GLP-1s aren't appropriate for you. Also ask which GLP-1s the plan does cover. Since Foundayo launched in April 2026, many plans simply haven't reviewed it yet — the denial may be a calendar problem, not a clinical judgment.
- What if my plan requires step therapy?
- Ask for the plan's step-therapy list, then have your prescriber request an exception if you've already tried the required drug, can't tolerate it, or have a contraindication. If the preferred drug genuinely fits you, taking it may be the faster path to treatment.
- I already lost weight on a GLP-1 — do I still qualify?
- Often yes. For the Medicare GLP-1 Bridge, eligibility is judged at the time you started GLP-1 therapy, so your prescriber can attest you met the BMI criteria back then even if your BMI is lower now. For commercial plans, ask whether continuation-of-therapy criteria use your baseline BMI.
- Can I pay cash while my appeal is pending?
- Yes, if your prescriber keeps you on it. Foundayo's cash price is $149–$349/month by dose through LillyDirect or Ro, no insurance approval needed. If your appeal succeeds later, you can switch to insurance pricing — as low as $25/month with the savings card on a covered commercial plan — at a future refill.
- Does Medicare cover Foundayo after a denial?
- Starting July 1, 2026, eligible Medicare Part D enrollees can get Foundayo for a $50 monthly copay through the Medicare GLP-1 Bridge, which runs through December 31, 2027. Eligibility requires eligible Part D drug coverage plus meeting BMI-based clinical tiers, and your prescriber files the authorization through the central CMS process.
- What is an external review, and how fast is it?
- An external review puts your case in front of an independent reviewer outside your insurance company, and the decision binds the insurer. You must request it within 4 months of the final internal denial; standard reviews are decided within 45 days, expedited within 72 hours.
- Is there a generic or compounded orforglipron?
- No. Orforglipron has no FDA-approved generic, and compounded drugs are not FDA-approved. Treat anything sold as 'generic Foundayo' or 'compounded orforglipron' as a serious red flag, not a lower-cost substitute.
- Can my doctor refuse to help with the appeal?
- Yes — a clinician can decline if they believe the criteria aren't met or the medication isn't appropriate for you. You can request copies of your records, ask which criteria they think are unmet, or seek an evaluation from another qualified clinician, including a telehealth provider.
Related guides
- How to Appeal a Wegovy Denial (2026)
- How to Appeal a Zepbound Denial (2026)
- Foundayo Prior Authorization: Full Guide
- GLP-1 Formulary Exception: Step-by-Step
- How to Bypass Step Therapy for GLP-1s
- Medicare GLP-1 Bridge Program — Full Guide
- External Review: Your Final Appeal Right
- GLP-1 Appeal Levels Explained
Sources
- 1.FDA — Foundayo (orforglipron) Approval and Prescribing Information (April 1, 2026): https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-foundayo
- 2.Eli Lilly — Foundayo pricing, savings card, and LillyDirect: https://www.lillydirect.com/foundayo
- 3.Lilly — Foundayo full prescribing information (boxed warning: thyroid C-cell tumors; contraindications; drug interactions): https://pi.lilly.com/us/foundayo-uspi.pdf
- 4.HealthCare.gov — How to appeal a health plan decision (180-day internal, 4-month external, 30/60-day plan decisions): https://www.healthcare.gov/appeal-insurance-company-decision/appeals/
- 5.CMS — Medicare GLP-1 Bridge Program (July 1, 2026 – Dec 31, 2027; $50 copay; three eligibility tiers; baseline BMI rule; Extra Help non-applicability): https://www.cms.gov/newsroom/fact-sheets/medicare-glp-1-bridge-demonstration
- 6.KFF — Analysis of ACA marketplace claims appeals (2024): <1% appealed; 66% upheld by insurer: https://www.kff.org/private-insurance/issue-brief/claims-denials-and-appeals-in-aca-marketplace-plans/
- 7.KFF — Analysis of Medicare Advantage prior-authorization denials (2024): 11.5% appealed; 80.7% partly or fully overturned: https://www.kff.org/medicare/issue-brief/medicare-advantage-prior-authorization-denials-appeals-and-outcomes/
- 8.Ro — GLP-1 Insurance Coverage Checker (contacts insurer, personalized coverage report): https://ro.co/weight-loss/glp1-insurance-checker/
- 9.Ro — How it works for insurance (Wegovy pen, Zepbound, Ozempic as insurance-covered; Foundayo as cash-pay): https://ro.co/weight-loss/insurance/
- 10.Ro — Foundayo pricing ($149–$299 cash-pay): https://ro.co/weight-loss/foundayo/
- 11.Sesame Care — GLP-1 provider options (provider choice, branded medications): https://sesamecare.com/service/online-weight-loss-program
Foundayo and orforglipron are trademarks of Eli Lilly and Company. This page is independent and not affiliated with Eli Lilly, Ro, or Sesame Care.